As of 2025-07-11, the EV/EBITDA ratio of Enanta Pharmaceuticals Inc (ENTA) is -0.91. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ENTA's latest enterprise value is 90.37 mil USD. ENTA's TTM EBITDA according to its financial statements is -98.94 mil USD. Dividing these 2 quantities gives us the above ENTA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.1x - 13.5x | 11.3x |
| Forward P/E multiples | 12.8x - 22.9x | 14.4x |
| Fair Price | (56.30) - (59.54) | (56.83) |
| Upside | -906.6% - -953.0% | -914.2% |
| Date | EV/EBITDA |
| 2025-07-09 | -0.95 |
| 2025-07-08 | -1.08 |
| 2025-07-07 | -1.06 |
| 2025-07-03 | -1.11 |
| 2025-07-02 | -1.13 |
| 2025-07-01 | -1.07 |
| 2025-06-30 | -1.04 |
| 2025-06-27 | -1.03 |
| 2025-06-26 | -1.03 |
| 2025-06-25 | -1.01 |
| 2025-06-24 | -0.99 |
| 2025-06-23 | -0.94 |
| 2025-06-20 | -0.96 |
| 2025-06-18 | -0.97 |
| 2025-06-17 | -0.93 |
| 2025-06-16 | -0.98 |
| 2025-06-13 | -1.03 |
| 2025-06-12 | -1.01 |
| 2025-06-11 | -1.12 |
| 2025-06-10 | -1.04 |
| 2025-06-09 | -1.03 |
| 2025-06-06 | -1.02 |
| 2025-06-05 | -0.96 |
| 2025-06-04 | -0.94 |
| 2025-06-03 | -0.96 |
| 2025-06-02 | -0.76 |
| 2025-05-30 | -0.69 |
| 2025-05-29 | -0.74 |
| 2025-05-28 | -0.67 |
| 2025-05-27 | -0.66 |
| 2025-05-23 | -0.66 |
| 2025-05-22 | -0.65 |
| 2025-05-21 | -0.66 |
| 2025-05-20 | -0.72 |
| 2025-05-19 | -0.69 |
| 2025-05-16 | -0.65 |
| 2025-05-15 | -0.57 |
| 2025-05-14 | -0.52 |
| 2025-05-13 | -0.54 |
| 2025-05-12 | -0.60 |
| 2025-05-09 | -0.54 |
| 2025-05-08 | -0.55 |
| 2025-05-07 | -0.50 |
| 2025-05-06 | -0.50 |
| 2025-05-05 | -0.58 |
| 2025-05-02 | -0.69 |
| 2025-05-01 | -0.71 |
| 2025-04-30 | -0.72 |
| 2025-04-29 | -0.66 |
| 2025-04-28 | -0.62 |